Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Clicks: 442
ID: 67590
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #1 of 12 articles by views in Kidney international

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The Apolipoprotein L1 (APOL1) risk variants G1 and G2 are associated with high rates of kidney disease in African Americans in genetic studies. However, our understanding of APOL1 biology has lagged far behind. Here we report that engineering G1 and G2 mutations on unnatural haplotype backgrounds instead of on the specific G1 and G2 haplotype backgrounds that occur in nature profoundly alters APOL1-mediated cytotoxicity in experimental systems. Thus, in addition to helping resolve some important controversies in the APOL1 field, our demonstration of the critical influence of haplotype background may apply more generally to the study of other genetic variants that cause or predispose to human disease.
Reference Key
lannon2019apolipoproteinkidney Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lannon, Herbert;Shah, Shrijal S;Dias, Leny;Blackler, Daniel;Alper, Seth L;Pollak, Martin R;Friedman, David J;
Journal Kidney international
Year 2019
DOI
S0085-2538(19)30777-X
URL
Keywords
chronic kidney disease haplotype focal segmental glomerulosclerosis apol1 trypanosome

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.